Newer drugs, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, exert beneficial effects across of a wide spectrum of cardiovascular diseases, and are indicated among patients with HF regardless of the cause [41]. This evidence concerns the gene SLC5A2 and hydrops fetalis.